- Advanced Therapies and Stem Cells
- Module code
Aim of this module
This module will enable trainees to develop their knowledge of stem cell transplantation and advanced therapies and improve understanding of the application in the treatment of a range of haematological disorders.
|# 1||Learning outcome 1||
Perform an audit of sample storage to ensure compliance with the Human Tissue Authority (HTA)
|# 2||Learning outcome 2,3||
Select the appropriate monitoring methods for patients treated with novel and emerging therapies which may interfere with standard assays
|# 3||Learning outcome 1,3,4||
Appraise a clinical trial protocol
|# 4||Learning outcome 1,2,3||
Measure CD34 positive stem cells in a donated sample by flow cytometry
|# 5||Learning outcome 1,3||
Interpret results of cfDNA assay and suggest further actions for treatment/therapy
|# 6||Learning outcome 1,3||
Prepare a case study where ALLO transplantation has been used for treatment
|# 7||Learning outcome 1,3||
Review post ALLO transplant monitoring data and advise on next steps and follow up
|# 8||Learning outcome 1,3||
Present a case report of a patient undergoing novel therapy as part of a clinical trial
|# 9||Learning outcome 1,3||
Assist with the clinical laboratory work-up of patients awaiting haemopoietic stem cell transplantation
|# 10||Learning outcome 1,3||
Present a case study of a patient undergoing treatment or treated with a personalised medicine strategy
Complete 2 Case-Based Discussions
Complete 2 DOPS or OCEs
Direct Observation of Practical Skills Titles
- Perform tests to monitor post-transplant engraftment.
- Draft a report for the results of a cfDNA assay.
- Select suitable blood products for a patient who has had a stem cell transplant.
- Assess patient eligibility for a clinical trial.
Observed Clinical Event Titles
- Discuss testing appropriateness with a healthcare professional.
- Obtain informed consent from a patient for a procedure, including an explanation of the risk and benefits of the procedure to the patient.
Practice in accordance with legislation regarding use of human tissue.
Apply laboratory techniques to support the use of stem cells in the treatment of haematological conditions.
Appraise the application of novel and evolving therapies in the treatment of haematological conditions.
Evaluate the application of gene therapy for the treatment for malignant and non-malignant haematology.
Clinical experiences help you to develop insight into your practice and greater understanding of your specialty. Clinical experiences should be included in your training plan and you may be asked to help organise your experiences. While Clinical Experiences are not assessed, reflections and observations from your experiences can be used to support evidence for competencies to demonstrate your awareness and appreciation of your specialty and it’s impact on patient care. You may find it helpful to capture thoughts from your experiences in your reflective log.
- Observe a stem cell harvest.
- Attend ward rounds and clinics at which patients are being worked up for or monitored following haematopoieticstem cell transplantation.
- Attend a multidisciplinary review meeting at which laboratory results are presented for patients awaiting transplant or being monitored following haematopoieticstem cell transplantation.
- Attend or access a patient forum or local support group to appreciate patient experiences and context.
- Shadow a nurse specialist providing pastoral care to patients.
Academic content (MSc in Clinical Science)
The academic parts of this module will be detailed and communicated to you by your university. Please contact them if you have questions regarding this module and its assessments. The module titles in your MSc may not be exactly identical to the work-based modules shown in the e-portfolio. Your modules will be aligned, however, to ensure that your academic and work-based learning are complimentary.
On successful completion of this module the trainee will be able to:
- Critically appraise the use of monoclonal antibodies in haematological disorders.
- Critically evaluate the role of stem cell, cord blood and CAR-T cells.
- Critique how gene therapy plays a role in the management of patients with malignant and non-malignant haematology.
- Clinical trials protocols and consent processes.
- Clinical indications.
- Sources and generation of stem cells- registries, cord blood.
- CAR-T cells.
- Personalised treatment protocols.
- Precision medicine.
Module assigned to
|Specialty code||Specialty title||Action|
|Specialty code SLS1-2-22||Specialty title Haematology & Transfusion Science ||Action View|